

Metastatic HER2-Positive Breast Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/ME0DBA2F3952EN.html>

Date: May 2024

Pages: 138

Price: US\$ 6,499.00 (Single User License)

ID: ME0DBA2F3952EN

Abstracts

The 7 major metastatic HER2-positive breast cancer markets are expected to exhibit a CAGR of 1.18% during 2024-2034.

The metastatic HER2-positive breast cancer market has been comprehensively analyzed in IMARC's new report titled "Metastatic HER2-Positive Breast Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Metastatic HER2 (human epidermal growth factor receptor 2)-positive breast cancer is an advanced stage of breast cancer characterized by the presence of HER2 protein overexpression. It tends to be more aggressive than other forms of cancer due to its accelerated growth and increased likelihood of spreading beyond the breast tissue. The symptoms of this illness may include a palpable lump in the breast or underarm, alterations in breast shape or size, skin dimpling, nipple changes, persistent pain, and bone fractures. As the cancer advances, it can spread to distant organs, such as the brain, bones, lungs, or liver, causing further complications. The diagnosis of metastatic HER2-positive breast cancer typically requires a combination of clinical findings and physical investigations. The healthcare provider will also perform numerous diagnostic procedures, including a mammogram or ultrasound, a biopsy of the tumor tissue to confirm HER2 positivity, and imaging studies to determine the extent of metastasis.

The increasing incidences of genetic variations in the BRCA1 and BRCA2 genes, resulting in uncontrolled growth and division of abnormal cells that originate in the breast tissue, are primarily driving the metastatic HER2-positive breast cancer market. In addition to this, the inflating utilization of innovative approaches, such as antibody-drug conjugates and immune checkpoint inhibitors, which help in harnessing the body's

immune response to combat cancerous cells, is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive therapies, including immunotherapies, bisphosphonates, and pain management strategies, aimed at enhancing patients' overall well-being and mitigating treatment-related complications, is further bolstering the market growth. Apart from this, the rising usage of precision medicine approaches, since they involve tailoring treatments based on the genetic makeup of the tumor, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of minimally invasive procedures, such as radiofrequency ablation and cryoablation to precisely target and eliminate tumor masses in individuals suffering from the illness is also augmenting the market growth. Furthermore, the escalating application of gene-targeting treatments that aim to correct or inhibit the overexpression of the HER2 gene is expected to drive the metastatic HER2-positive breast cancer market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the metastatic HER2-positive breast cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for metastatic HER2-positive breast cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the metastatic HER2-positive breast cancer market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the metastatic HER2-positive breast cancer market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the metastatic HER2-positive breast cancer market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current metastatic HER2-positive breast cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report: Market Insights

How has the metastatic HER2-positive breast cancer market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the metastatic HER2-positive breast cancer market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the metastatic HER2-positive breast cancer market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of metastatic HER2-positive breast cancer across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of metastatic HER2-positive breast cancer by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of metastatic HER2-positive breast cancer by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with metastatic HER2-positive breast cancer across the seven major markets?
What is the size of the metastatic HER2-positive breast cancer patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of metastatic HER2-positive breast cancer?
What will be the growth rate of patients across the seven major markets?

Metastatic HER2-Positive Breast Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for metastatic HER2-positive breast cancer drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the metastatic HER2-positive breast cancer market?

What are the key regulatory events related to the metastatic HER2-positive breast cancer market?

What is the structure of clinical trial landscape by status related to the metastatic HER2-positive breast cancer market?

What is the structure of clinical trial landscape by phase related to the metastatic HER2-positive breast cancer market?

What is the structure of clinical trial landscape by route of administration related to the metastatic HER2-positive breast cancer market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 METASTATIC HER2-POSITIVE BREAST CANCER - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 METASTATIC HER2-POSITIVE BREAST CANCER - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 METASTATIC HER2-POSITIVE BREAST CANCER - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)

- 7.7.3 Epidemiology by Age (?2018-2034?)
- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 METASTATIC HER2-POSITIVE BREAST CANCER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 METASTATIC HER2-POSITIVE BREAST CANCER - UNMET NEEDS

10 METASTATIC HER2-POSITIVE BREAST CANCER - KEY ENDPOINTS OF TREATMENT

11 METASTATIC HER2-POSITIVE BREAST CANCER - MARKETED PRODUCTS

- 11.1 List of Metastatic HER2-Positive Breast Cancer Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Perjeta (Pertuzumab) - Genentech
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results

- 11.1.1.5 Sales Across Major Markets
- 11.1.2 Tukysa (Tucatinib) - Seagen
 - 11.1.2.1 Drug Overview
 - 11.1.2.2 Mechanism of Action
 - 11.1.2.3 Regulatory Status
 - 11.1.2.4 Clinical Trial Results
 - 11.1.2.5 Sales Across Major Markets
- 11.1.3 Nerlynx (Neratinib) - Puma Biotechnology
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Margenzatm (Margetuximab-Cmkb) - MacroGenics
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Enhertu (Fam-Trastuzumab Deruxtecan-Nxki) - Daiichi Sankyo
 - 11.1.5.1 Drug Overview
 - 11.1.5.2 Mechanism of Action
 - 11.1.5.3 Regulatory Status
 - 11.1.5.4 Clinical Trial Results
 - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 METASTATIC HER2-POSITIVE BREAST CANCER - PIPELINE DRUGS

12.1 List of Metastatic HER2-Positive Breast Cancer Pipeline Drugs Across the Top 7 Markets

- 12.1.1 Pertuzumab - Genentech
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status
- 12.1.2 Inavolisib - Roche Pharma

- 12.1.2.1 Drug Overview
- 12.1.2.2 Mechanism of Action
- 12.1.2.3 Clinical Trial Results
- 12.1.2.4 Safety and Efficacy
- 12.1.2.5 Regulatory Status
- 12.1.3 Giredestrant - Roche Pharma
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status
- 12.1.4 ZN-A-1041 - Suzhou Zanrong Pharma
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action
 - 12.1.4.3 Clinical Trial Results
 - 12.1.4.4 Safety and Efficacy
 - 12.1.4.5 Regulatory Status
- 12.1.5 Palbociclib - Pfizer
 - 12.1.5.1 Drug Overview
 - 12.1.5.2 Mechanism of Action
 - 12.1.5.3 Clinical Trial Results
 - 12.1.5.4 Safety and Efficacy
 - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. METASTATIC HER2-POSITIVE BREAST CANCER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. METASTATIC HER2-POSITIVE BREAST CANCER – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 METASTATIC HER2-POSITIVE BREAST CANCER - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Metastatic HER2-Positive Breast Cancer - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Metastatic HER2-Positive Breast Cancer - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Metastatic HER2-Positive Breast Cancer - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Metastatic HER2-Positive Breast Cancer - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 Metastatic HER2-Positive Breast Cancer - Access and Reimbursement

Overview

15.4 Market Scenario - Germany

15.4.1 Metastatic HER2-Positive Breast Cancer - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 Metastatic HER2-Positive Breast Cancer - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

15.4.2.2 Market Forecast by Therapies (2024-2034)

15.4.3 Metastatic HER2-Positive Breast Cancer - Access and Reimbursement

Overview

15.5 Market Scenario - France

15.5.1 Metastatic HER2-Positive Breast Cancer - Market Size

15.5.1.1 Market Size (2018-2023)

15.5.1.2 Market Forecast (2024-2034)

15.5.2 Metastatic HER2-Positive Breast Cancer - Market Size by Therapies

15.5.2.1 Market Size by Therapies (2018-2023)

15.5.2.2 Market Forecast by Therapies (2024-2034)

15.5.3 Metastatic HER2-Positive Breast Cancer - Access and Reimbursement

Overview

15.6 Market Scenario - United Kingdom

15.6.1 Metastatic HER2-Positive Breast Cancer - Market Size

15.6.1.1 Market Size (2018-2023)

15.6.1.2 Market Forecast (2024-2034)

15.6.2 Metastatic HER2-Positive Breast Cancer - Market Size by Therapies

15.6.2.1 Market Size by Therapies (2018-2023)

15.6.2.2 Market Forecast by Therapies (2024-2034)

15.6.3 Metastatic HER2-Positive Breast Cancer - Access and Reimbursement

Overview

15.7 Market Scenario - Italy

15.7.1 Metastatic HER2-Positive Breast Cancer - Market Size

15.7.1.1 Market Size (2018-2023)

15.7.1.2 Market Forecast (2024-2034)

15.7.2 Metastatic HER2-Positive Breast Cancer - Market Size by Therapies

15.7.2.1 Market Size by Therapies (2018-2023)

15.7.2.2 Market Forecast by Therapies (2024-2034)

15.7.3 Metastatic HER2-Positive Breast Cancer - Access and Reimbursement

Overview

15.8 Market Scenario - Spain

15.8.1 Metastatic HER2-Positive Breast Cancer - Market Size

15.8.1.1 Market Size (2018-2023)

15.8.1.2 Market Forecast (2024-2034)

15.8.2 Metastatic HER2-Positive Breast Cancer - Market Size by Therapies

15.8.2.1 Market Size by Therapies (2018-2023)

15.8.2.2 Market Forecast by Therapies (2024-2034)

15.8.3 Metastatic HER2-Positive Breast Cancer - Access and Reimbursement

Overview

15.9 Market Scenario - Japan

15.9.1 Metastatic HER2-Positive Breast Cancer - Market Size

15.9.1.1 Market Size (2018-2023)

15.9.1.2 Market Forecast (2024-2034)

15.9.2 Metastatic HER2-Positive Breast Cancer - Market Size by Therapies

15.9.2.1 Market Size by Therapies (2018-2023)

15.9.2.2 Market Forecast by Therapies (2024-2034)

15.9.3 Metastatic HER2-Positive Breast Cancer - Access and Reimbursement

Overview

16 METASTATIC HER2-POSITIVE BREAST CANCER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 METASTATIC HER2-POSITIVE BREAST CANCER MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 METASTATIC HER2-POSITIVE BREAST CANCER MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Metastatic HER2-Positive Breast Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/ME0DBA2F3952EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ME0DBA2F3952EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

